FDA warns of valsartan shortage, provides risk estimates for carcinogenic impurity

People taking the widely prescribed blood-pressure medication valsartan may have been exposed to a probable human carcinogen for at least four years after a change in the manufacturing process introduced the impurity, according to an update from the FDA’s ongoing investigation into the contaminants that have been found in a series of angiotensin II receptor blockers (ARBs).

Measures of subclinical atherosclerosis differ by sex in heavy smokers

An analysis of more than 5,000 heavy smokers who underwent CT scans revealed that male smokers experienced a greater burden of coronary artery calcium (CAC) while women tended to have higher volumes of thoracic aorta calcium (TAC). Both measures were associated with increased cardiovascular and all-cause mortality, researchers reported in JACC: Cardiovascular Imaging.